Drug
Pyrotinib plus Capecitabine
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
0(0%)
Phase Distribution
Ph phase_2
2
67%
Ph phase_3
1
33%
Phase Distribution
0
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Other(2)
Detailed Status
unknown2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 22 (66.7%)
Phase 31 (33.3%)
Trials by Status
unknown267%
not_yet_recruiting133%
Recent Activity
0 active trials
Showing 3 of 3
not_yet_recruitingphase_2
Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs
NCT06475443
unknownphase_2
A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer
NCT03691051
unknownphase_3
Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)
NCT03080805
Clinical Trials (3)
Showing 3 of 3 trials
NCT06475443Phase 2
Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs
NCT03691051Phase 2
A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer
NCT03080805Phase 3
Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3